Sanofi gets FDA approval for NovoLog insulin biosimilar
Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...
Novo Nordisk is facing its worst week this year — after that Hims & Hers Super Bowl ad
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
MM&M3d
‘Check before you inject’: Novo bites back at Hims & Hers Super Bowl ad
Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.
STAT3d
Vertex pain pill dominates earnings call discussion
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
hemophilianewstoday3d
Antibody therapy Mim8 seen effective in hemophilia A children
Antibody therapy Mim8 was found to be safe and effective for controlling bleeds in children with hemophilia A in a Phase 3 ...
Is Novo Nordisk's Bottom Here? Oversold Status Below 10Y P/E Lows
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
Pharm Exec4d
Mim8 Demonstrates Promising Results in Pediatric Patients with Hemophilia A
Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.
PharmiWeb4d
Phase 3 FRONTIER3 interim analysis data presented…
Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...